356 related articles for article (PubMed ID: 26450456)
21. Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources.
Heller SR; Frier BM; Hersløv ML; Gundgaard J; Gough SC
Diabet Med; 2016 Apr; 33(4):471-7. PubMed ID: 26179360
[TBL] [Abstract][Full Text] [Related]
22. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial.
Bode BW; Buse JB; Fisher M; Garg SK; Marre M; Merker L; Renard E; Russell-Jones DL; Hansen CT; Rana A; Heller SR;
Diabet Med; 2013 Nov; 30(11):1293-7. PubMed ID: 23710902
[TBL] [Abstract][Full Text] [Related]
23. Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia.
Goldenberg RM; Aroda VR; Billings LK; Christiansen ASL; Meller Donatsky A; Parvaresh Rizi E; Podgorski G; Raslova K; Klonoff DC; Bergenstal RM
Diabetes Obes Metab; 2021 Nov; 23(11):2572-2581. PubMed ID: 34322967
[TBL] [Abstract][Full Text] [Related]
24. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials.
Ratner RE; Gough SC; Mathieu C; Del Prato S; Bode B; Mersebach H; Endahl L; Zinman B
Diabetes Obes Metab; 2013 Feb; 15(2):175-84. PubMed ID: 23130654
[TBL] [Abstract][Full Text] [Related]
25. Insulin-based strategies to prevent hypoglycaemia during and after exercise in adult patients with type 1 diabetes on pump therapy: the DIABRASPORT randomized study.
Franc S; Daoudi A; Pochat A; Petit MH; Randazzo C; Petit C; Duclos M; Penfornis A; Pussard E; Not D; Heyman E; Koukoui F; Simon C; Charpentier G
Diabetes Obes Metab; 2015 Dec; 17(12):1150-7. PubMed ID: 26264812
[TBL] [Abstract][Full Text] [Related]
26. Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials.
DeVries JH; Bailey TS; Bhargava A; Gerety G; Gumprecht J; Heller S; Lane W; Wysham CH; Zinman B; Bak BA; Hachmann-Nielsen E; Philis-Tsimikas A
Diabetes Obes Metab; 2019 Mar; 21(3):622-630. PubMed ID: 30362250
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension.
Mathieu C; Hollander P; Miranda-Palma B; Cooper J; Franek E; Russell-Jones D; Larsen J; Tamer SC; Bain SC;
J Clin Endocrinol Metab; 2013 Mar; 98(3):1154-62. PubMed ID: 23393185
[TBL] [Abstract][Full Text] [Related]
28. Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used.
Norwood P; Chen R; Jaeckel E; Lingvay I; Jarlov H; Lehmann L; Heller S
Diabetes Obes Metab; 2017 Nov; 19(11):1562-1569. PubMed ID: 28417535
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
Heise T; Hövelmann U; Nosek L; Hermanski L; Bøttcher SG; Haahr H
Expert Opin Drug Metab Toxicol; 2015; 11(8):1193-201. PubMed ID: 26086190
[TBL] [Abstract][Full Text] [Related]
30. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
[TBL] [Abstract][Full Text] [Related]
31. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.
Birkeland KI; Home PD; Wendisch U; Ratner RE; Johansen T; Endahl LA; Lyby K; Jendle JH; Roberts AP; DeVries JH; Meneghini LF
Diabetes Care; 2011 Mar; 34(3):661-5. PubMed ID: 21270174
[TBL] [Abstract][Full Text] [Related]
32. Comparison of glycemic variability in Japanese patients with type 1 diabetes receiving insulin degludec versus insulin glargine using continuous glucose monitoring: A randomized, cross-over, pilot study.
Onda Y; Nishimura R; Ando K; Takahashi H; Tsujino D; Utsunomiya K
Diabetes Res Clin Pract; 2016 Oct; 120():149-55. PubMed ID: 27562434
[TBL] [Abstract][Full Text] [Related]
33. Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus.
Philis-Tsimikas A; Astamirova K; Gupta Y; Haggag A; Roula D; Bak BA; Fita EG; Nielsen AM; Demir T
Diabetes Res Clin Pract; 2019 Jan; 147():157-165. PubMed ID: 30448451
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective.
Evans M; Wolden M; Gundgaard J; Chubb B; Christensen T
Diabetes Obes Metab; 2014 Apr; 16(4):366-75. PubMed ID: 24373113
[TBL] [Abstract][Full Text] [Related]
35. Comparative safety and efficacy of insulin degludec with insulin glargine in type 2 and type 1 diabetes: a meta-analysis of randomized controlled trials.
Zhang XW; Zhang XL; Xu B; Kang LN
Acta Diabetol; 2018 May; 55(5):429-441. PubMed ID: 29423761
[TBL] [Abstract][Full Text] [Related]
36. Day-to-Day and Within-Day Variability in Glucose-Lowering Effect Between Insulin Degludec and Insulin Glargine (100 U/mL and 300 U/mL): A Comparison Across Studies.
Heise T; Kaplan K; Haahr HL
J Diabetes Sci Technol; 2018 Mar; 12(2):356-363. PubMed ID: 28946756
[TBL] [Abstract][Full Text] [Related]
37. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON).
Mathieu C; Rodbard HW; Cariou B; Handelsman Y; Philis-Tsimikas A; Ocampo Francisco AM; Rana A; Zinman B;
Diabetes Obes Metab; 2014 Jul; 16(7):636-44. PubMed ID: 24443830
[TBL] [Abstract][Full Text] [Related]
38. [The efficacy and safety of insulin degludec versus insulin glargine in insulin-naive subjects with type 2 diabetes: results of a Chinese cohort from a multinational randomized controlled trial].
Mu YM; Guo LX; Li L; Li YM; Xu XJ; Li QM; Xu MT; Zhu LY; Yuan GY; Liu Y; Xu C; Wang ZJ; Shen FX; Luo Y; Liu JY; Li QF; Wang WH; Lai XY; Xu HF; Pan CY
Zhonghua Nei Ke Za Zhi; 2017 Sep; 56(9):660-666. PubMed ID: 28870034
[No Abstract] [Full Text] [Related]
39. Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial.
Kumar A; Franek E; Wise J; Niemeyer M; Mersebach H; Simó R
PLoS One; 2016; 11(10):e0163350. PubMed ID: 27760129
[TBL] [Abstract][Full Text] [Related]
40. Modified release terbutaline (SKP1052) for hypoglycaemia prevention: a proof-of-concept study in people with type 1 diabetes mellitus.
Nosek L; Cardot JM; Owens DR; Ibarra P; Bagate K; Vergnault G; Kaiser K; Fischer A; Heise T
Diabetes Obes Metab; 2012 Dec; 14(12):1137-44. PubMed ID: 22988932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]